PDCD1 and pneumonitis: Based on the subgroup analysis results (Fig. S3A, SFigure 4, SFigure 5, and SFigure 6), we found that the risk of pneumonitis in UC patients receiving PD-1 inhibitors was the highest among all tumor types.